Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 13:2023:9355672.
doi: 10.1155/2023/9355672. eCollection 2023.

Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience

Rodolfo Guelman  1 , Ariel Sánchez  2 , Mariela Varsavsky  1 , Lucas R Brun  3   4 , María Laura García  5 , Marcelo Sarli  6 , Rey Paula  6 , Vanina Farias  6 , María Belén Zanchetta  6 , Evangelina Giacoia  7 , Helena Salerni  8 , Laura Maffei  9 , Valeria Premrou  9 , Beatriz Oliveri  10 , María Lorena Brance  3   11 , Magdalena Pavlove  12 , Silvia Karlsbrum  12 , María Silvia Larroudé  13 , Pablo René Costanzo  1
Affiliations

Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience

Rodolfo Guelman et al. Int J Endocrinol. .

Abstract

Purpose: To evaluate the effect of teriparatide (TPTD) on bone mineral density (BMD) and bone markers under clinical practice conditions. To assess whether the results in real-life match those published in clinical trials.

Methods: Cross-sectional study of postmenopausal women treated with TPTD for at least 12 months.

Results: 264 patients were included in the study. Main characteristics are as follows: age: 68.7 ± 10.2 years, previous fractures: 57.6%, and previously treated with antiresorptive (AR-prior): 79%. All bone turnover markers studied significantly increased after 6 months. CTX and BGP remained high up to 24 months, but total and bone alkaline phosphatase returned to basal values at month 18. There was a significant increase in lumbar spine (LS) BMD after 6 months (+6.2%), with a maximum peak at 24 months (+13%). Femoral neck (FN) and total hip (TH) BMD showed a significant increase later than LS (just at month 12), reaching a maximum peak at month 24 (FN + 7.9% and TH + 5.5%). A significant increase in LS BMD was found from month 6 to month 24 compared to basal in both AR-naïve, and AR-prior patients (+16.7% and +10.5%, respectively), without significant differences between the two groups. Comparable results were found in FN and TH BMD. Main conclusions. As reported in real-life clinical studies, treatment of osteoporotic postmenopausal women with TPTD induced a significant increase in bone turnover markers from month 6 onward and an increase in BMD from months 6-12 with continuous gain up to month 24. The real-life results of our study matched the results of randomized clinical trials. In addition, TPTD induced an increase in BMD, regardless of the previous use of AR.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Changes in bone mineral density during treatment with teriparatide. Wilcoxon signed-rank test. Mean ± SEM. ∗Indicates significant differences vs. basal (p < 0.05). #Indicates significant differences vs. previous (p < 0.05).
Figure 2
Figure 2
Changes in bone formation and resorption markers during treatment with teriparatide. Wilcoxon signed-rank test. Mean ± SEM. ∗Indicates significant differences vs. basal (p < 0.05).
Figure 3
Figure 3
Changes in BMD in antiresorptive (AR)-naïve vs. AR-prior patients. Wilcoxon signed-rank test. Mean ± SEM. ∗Indicates significant differences vs. basal.
See this image and copyright information in PMC

References

    1. Jiang Y., Zhao J. J., Mitlak B. H., Wang O., Genant H. K., Eriksen E. F. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone and Mineral Research . 2003;18(11):1932–1941. doi: 10.1359/jbmr.2003.18.11.1932. - DOI - PubMed
    1. Dempster D. W., Cosman F., Kurland E. S., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. Journal of Bone and Mineral Research . 2001;16(10):1846–1853. doi: 10.1359/jbmr.2001.16.10.1846. - DOI - PubMed
    1. Compston J. E. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone . 2007;40(6):1447–1452. doi: 10.1016/j.bone.2006.09.008. - DOI - PubMed
    1. Ma Y. L., Zeng Q. Q., Chiang A. Y., et al. Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone . 2014;59:139–147. doi: 10.1016/j.bone.2013.11.011. - DOI - PubMed
    1. Neer R. M., Arnaud C. D., Zanchetta J. R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine . 2001;344(19):1434–1441. doi: 10.1056/nejm200105103441904. - DOI - PubMed